Let's spread the word about Immunotherapy! Click to share this page with your community.

Immunotherapy Side Effects: What Patients Need to Know

Immunotherapy—a class of treatments that utilize the body’s immune system—has begun to revolutionize the landscape of cancer care. Due to the incredible power of the immune system, immunotherapy has been able to provide remarkable benefits for patients with a number of cancer type, including those for which there were previously no effective options. However, sometimes activating the immune system against cancer may lead to side effects and even autoimmune responses against healthy tissues.

In this webinar for patients and caregivers, Jeffrey S. Weber, M.D., Ph.D., of NYU Langone Health discusses our current understanding of the side effects that may result from immunotherapy as well as current strategies that are being explored to minimize these potentially harmful side effects and improve the patient experience.

Dr. Jeffrey S Weber of NYU LangoneDr. Jeffrey S. Weber is the deputy director of NYU Langone Health’s Perlmutter Cancer Center, where he works with a multidisciplinary team of medical and surgical oncologists, dermatologists, and pathologists to treat patients with melanomas ranging from the most common to the most complex.

Dr. Weber works at the forefront of the immunotherapy field, and his clinical and research interesting involve novel immune-based strategies to treat patients with melanoma as well as manage the side effects of these treatments. As part of these efforts, he remains involved in a variety of clinical trials, including those evaluating melanoma vaccines, cellular immunotherapies, among other new approaches against melanoma. He is also the principal investigator of several ongoing studies funded by the National Cancer Institute, including trials in clinical drug development and managing the autoimmune side effects of immunotherapy for melanoma. In the past, he has served as the principal investigator and director of Moffitt Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant for skin cancer and melanoma research from the National Cancer Institute. He also serves as the codirector of the Melanoma Research Program, where he oversees work in experimental therapeutics, and currently sit on the scientific advisory boards of cancer-related biotechnology companies and numerous cancer institutions and foundations.

The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. The 2020 series is made possible with generous support from Bristol-Myers Squibb, ALkermes, and Foundation Medicine.
 
Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.

Bristol Myers Squibb; Alkermes; and Foundation Medicine

*Immunotherapy results may vary from patient to patient.

Top